Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation, 128 16
F. McAlister, N. Wiebe, J. Ezekowitz, A. Leung, P. Armstrong (2009)
Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.Annals of internal medicine, 150 11
Genevieve Flannery, R. Gehrig-Mills, B. Billah, H. Krum (2008)
Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.The American journal of cardiology, 101 6
S. Arnold, J. Spertus, F. Masoudi, S. Daugherty, T. Maddox, Yan Li, J. Dodson, P. Chan (2013)
Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.Journal of the American College of Cardiology, 62 19
S. Thackray, J. Ghosh, G. Wright, K. Witte, N. Nikitin, G. Kaye, A. Clark, A. Tweddel, J. Cleland (2006)
The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers.American heart journal, 152 4
Theophilus Owan, D. Hodge, R. Herges, S. Jacobsen, V. Roger, M. Redfield (2006)
Trends in prevalence and outcome of heart failure with preserved ejection fraction.The New England journal of medicine, 355 3
M. Gheorghiade, N. Albert, A. Curtis, J. Heywood, M. McBride, P. Inge, M. Mehra, C. O'connor, D. Reynolds, M. Walsh, C. Yancy, G. Fonarow (2012)
Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF.Congestive heart failure, 18 1
D. DiFrancesco (2003)
If inhibition: a novel mechanism of actionEuropean Heart Journal Supplements, 5
CIBIS-II Committees (1999)
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 353
MS Nieminen, D Brutsaert, K Dickstein, H Drexler, F Follath, VP Harjola (2006)
EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of populationEur Heart J, 27
J. Juenger, D. Schellberg, S. Kraemer, A. Haunstetter, C. Zugck, W. Herzog, M. Haass (2002)
Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variablesHeart, 87
AP Maggioni, U Dahlström, G Filippatos, O Chioncel, MC Leiro, J Drozdz, F Fruhwald, L Gullestad, D Logeart, M Metra, J Parissis, H Persson, P Ponikowski, M Rauchhaus, A Voors, OW Nielsen, F Zannad, L Tavazzi (2010)
Heart Failure Association of ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)Eur J Heart Fail, 12
H. Huikuri, V. Jokinen, M. Syvänne, Markku Nieminen, K. Airaksinen, Markku Ikäheimo, Juhani Koistinen, H. Kauma, Antero Kesäniemi, Silja Majahalme, Kari Niemelä, M. Frick (1999)
Heart rate variability and progression of coronary atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology, 19 8
Michael Bristow, Michael Bristow, Niki Kantrowitz, Niki Kantrowitz, Robert Ginsburg, Robert Ginsburg, M. Fowler, M. Fowler (1985)
Beta-adrenergic function in heart muscle disease and heart failure.Journal of molecular and cellular cardiology, 17 Suppl 2
K. Dracup, J. Walden, L. Stevenson, Brecht Ml (1992)
Quality of life in patients with advanced heart failure.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 11 2 Pt 1
K. Fox, J. Borer, A. Camm, N. Danchin, R. Ferrari, J. Sendón, P. Steg, J. Tardif, L. Tavazzi, M. Tendera (2007)
Resting heart rate in cardiovascular disease.Journal of the American College of Cardiology, 50 9
J. Setaro, J. Setaro, B. Zaret, B. Zaret, D. Schulman, D. Schulman, H. Black, H. Black, R. Soufer, R. Soufer (1990)
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.The American journal of cardiology, 66 12
J. McMurray, S. Adamopoulos, S. Anker, A. Auricchio, M. Böhm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M. Gómez-Sánchez, T. Jaarsma, L. Køber, G. Lip, A. Maggioni, A. Parkhomenko, B. Pieske, B. Popescu, P. Rønnevik, F. Rutten, J. Schwitter, P. Seferovic, J. Stȩpińska, P. Trindade, A. Voors, F. Zannad, A. Zeiher, J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, Ž. Reiner, U. Sechtem, P. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, L. Bonet, P. Avraamides, Hisham Lamin, M. Brignole, A. Coca, P. Cowburn, H. Dargie, P. Elliott, F. Flachskampf, Guido Guida, S. Hardman, B. Iung, B. Merkely, C. Mueller, J. Nanas, O. Nielsen, S. Ørn, J. Parissis, P. Ponikowski (2012)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012European Journal of Heart Failure, 14
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 62 16
M. Fowler, S. Lottes, J. Nelson, M. Lukas, E. Gilbert, B. Greenberg, B. Massie, W. Abraham, J. Franciosa (2007)
β-Blocker dosing in community-based treatment of heart failureAmerican Heart Journal, 153
A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, G. Westergren, M. Thimell, D. Allaf, J. Vítovec, J. Aldershvile, M. Halinen, R. Dietz, K. Neuhaus, A. Jánosi, G. Thorgeirsson, P. Dunselman, L. Gullestad, J. Kuch, J. Herlitz, P. Rickenbacher, S. Ball, S. Gottlieb, P. Deedwania, G. Vandenhoven, I. Novakova, S. Danker, M. Lundström, W. Meyer-Sabellek, I. Balla, M. Sveinsdóttir, B. Dorhout, A. Hildebrandt, I. Szczurko, C. Larsson, E. Bucher, E. Scott, D. Dwyer, D. Julian, D. DeMets, K. Chatterjee, J. Feyzi, S. Lehto, P. Karpati, W. Motz, O. Samuelsson, J. Viersma, B. Andersson, C. Berthe, J. Boutefeu, G. Boxho, P. Decroly, J. Derbaudrenghien, J. Pirlet, P. Henry, G. Heyndrickx, L. Missault, M. Nannan, P. Timmermans, J. Vachiéry, W. Mieghem, J. Vandenbossche, K. Dvořák, M. Herold, J. Hradec, A. Kana, P. Petr, J. Rybka, J. Šmid, P. Svítil, J. Toman, E. Agner, O. Amtorp, K. Egstrup, P. Eliasen, C. Gøtzsche, P. Hildebrandt, A. Johannesen, P. Kaiser-Nielsen, H. Nielsen, P. Nielsen, F. Pedersen, J. Nielsen, K. Skagen, T. Honkanen, E. Hussi, J. Juvonen, H. Jääskeläinen, J. Rinne, T. Salonen, D. Andresen, H. Berwing, Bethge, Beythien, Bischoff, Bundschu, Daniel, Darius, Delius, Drude, Dingerkus, Dück, Eichler, Fach, A. Förster, Girth, Goss, Hahn, Hambrecht, G. Hauf, Heinemann, Hepp, Janka, Klocke, Konz, B. Krosse, Kühlkamp, Lewek, B. Lüderitz, Löbe, Maier, Melchior, Müller, Mäurer, Nast, Neuhaus, Obst, Odemar, K. Olshausen, Pomykaj, K. Schmailzl, Schrader, Schröder, P. Schwimmbeck, M. Sigmund, Simon, Strasser, Thilo, Vöhringer, H. Völler, Weibrodt, Wirtz, I. Czuriga, M. Hetey, A. Katona, M. Lengyel, A. Nyárádi, A. Rednik, K. Sándori, P. Szabó, J. Tarján, J. Tenczer, S. Timar, P. Vályi, G. Veress, K. Zámolyi, B. Öze, G. Thorgeirsson, G. Thorgeirsson, P. Bernink, A. Bredero, R. Breedveld, P. Breuls, J. Bucx, J. Cornel, P. Milliano, P. Dunselman, B. Hamer, N. Holwerda, J. Hoogsteen, J. Hoorntje, J. Kragten, A. Liem, G. Linssen, H. Michels, A. Misier, H. Schaafsma, P. Sijbring, R. Taverne, L. Kempen, R. Stralen, P. Veldhuisen, M. Veerhoek, C. Werter, J. Wesdorp, A. Willems, A. Withagen, P. Zwart, R. Bjørnerheim, M. Dahle, K. Dickstein, G. Frøland, T. Gundersen, K. Hofsoy, T. Hole, T. Johansen, J. Mannsverk, P. Nesje, T. Omland, C. Sjödin, P. Smith, H. Tjonndal, O. Vikesdal, K. Waagé, Adamus, K. Jaworska, P. Kołodziej, Z. Kornacewicz‐Jach, M. Krzeminska-Pakula, J. Piotrowski, W. Piwowarska, A. Stogowski, J. Wodniecki, K. Wrabec, P. Ahlström, S. Ekdahl, L. Hemmingson, L. Holmberg, B. Lernfelt, H. Widgren, K. Ångman, P. Erne, P. Mohacsi, R. Polikar, H. Schläpfer, P. Batin, K. Berkin, T. Callaghan, J. Forfar, M. Frenneaux, R. Greenbaum, M. Maltz, D. Murdoch, G. Reynolds, J. Stephens, A. Struthers, J. Swan, G. Tildesley, A. Abbasi, P. Alagona, J. Alderman, M. Alipour, Jeffrey Anderson, Z. Ansari, M. Ashraf, B. Beanblossom, S. Bennett, D. Benvenuti, M. Berk, R. Bhalla, S. Bilazarian, K. Browne, C. MBuchter, R. Carlson, C. Carlson, K. Danisa, I. Dauber, M. Dewood, G. Dennish, D. Denny, R. Dibianco, P. Diller, M. Dunlap, K. Dowd, A. Edmiston, M. Shahawy, U. Elkayam, J. Farnham, P. Fenster, S. Friedman, T. Heywood, J. Galichia, M. Geller, J. Ghali, M. Gheorghiade, T. Giles, R. Gillespe, G. Goldberg, M. Goldberg, D. Goldscher, G. Gooden, M. Goodman, L. Goodman, J. Gorwit, S. Gottlieb, A. Gradman, D. Grech, T. Hack, J. Hall, M. Hattenhauer, M. Higginbotham, S. Hutchins, M. Imburgia, B. Iteld, B. Jackson, S. Jafri, W. Jauch, S. Jennison, B. Kahn, W. Kao, K. Kaplan, R. Karlsberg, H. Kennedy, J. Kennedy, L. Kirkegaard, D. Kraus, K. Labresh, L. Lalonde, M. Lesser, R. Levites, M. Lévy, R. Lewis, I. Loh, H. Madyoon, F. Maislos, D. Mann, G. Maurice, A. Nisar, W. Old, J. Pappas, K. Phadke, S. Promisloff, A. Rashkow, B. Reeves, J. Rosen, M. Rotman, T. Saleem, S. Savran, R. Shah, Y. Shalev, J. Shanes, M. O'Shaughnessy, B. Silverman, R. Steingart, L. Swenson, K. Syed, U. Thadani, R. Thorsen, M. Tonkon, R. Touchon, G. Uhl, K. Vaska, S. Wagner, C. Weaver, R. Weiss, W. Wickemeyer, H. Willens, J. Wilson, R. Wright, L. Yellen (1999)
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 353
Hung Mj, Cherng Wj, Kuo Lt, Wang Ch (2002)
Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure.International Journal of Clinical Practice, 56
J. Reil, M. Hohl, G. Reil, H. Granzier, M. Kratz, A. Kazakov, P. Fries, A. Müller, M. Lenski, F. Custodis, S. Gräber, G. Fröhlig, P. Steendijk, H. Neuberger, M. Böhm (2013)
Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.European heart journal, 34 36
N. Kawashiro, H. Kasanuki, H. Ogawa, N. Matsuda, N. Hagiwara (2008)
Clinical characteristics and outcome of hospitalized patients with congestive heart failure: results of the HIJC-HF registry.Circulation journal : official journal of the Japanese Circulation Society, 72 12
F. Sarullo, G. Fazio, D. Puccio, S. Fasullo, S. Paterna, S. Novo, P. Pasquale (2010)
Impact of ‘‘Off-Label’’ Use of Ivabradine on Exercise Capacity, Gas Exchange, Functional Class, Quality of Life, and Neurohormonal Modulation in Patients With Ischemic Chronic Heart FailureJournal of Cardiovascular Pharmacology and Therapeutics, 15
WH Frishman (1998)
CarvedilolN Engl J Med, 339
R. Willenheimer, D. Veldhuisen, B. Silke, E. Erdmann, F. Follath, H. Krum, P. Ponikowski, A. Skene, L. Ven, P. Verkenne, P. Lechat (2005)
Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) IIICirculation, 112
R. Stafford, D. Radley (2003)
The underutilization of cardiac medications of proven benefit, 1990 to 2002.Journal of the American College of Cardiology, 41 1
M Böhm, K Swedberg, M Komajda, JS Borer, I Ford, A Dubost-Brama, G Lerebours, L Tavazzi (2010)
SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialLancet, 376
N. Kawashiro, H. Kasanuki, H. Ogawa, N. Matsuda, N. Hagiwara (2008)
Clinical Characteristics and Outcome of Hospitalized Patients With Congestive Heart FailureCirculation, 72
M. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, F. Follath, V. Harjola, M. Hochadel, M. Komajda, Johan Lassus, J. López-Sendón, P. Ponikowski, L. Tavazzi (2006)
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.European heart journal, 27 22
M. Ackerman, S. Priori, S. Willems, C. Berul, R. Brugada, H. Calkins, A. Camm, P. Ellinor, M. Gollob, R. Hamilton, R. Hershberger, D. Judge, H. Marec, W. McKenna, E. Schulze-Bahr, C. Semsarian, J. Towbin, H. Watkins, A. Wilde, C. Wolpert, D. Zipes (2011)
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 13 8
H. Strömer, M. Camerer (2006)
Adherence to guidelines is a predictor of outcome in chronic heart failure: the Mahler survey.European heart journal, 27 2
A. Bucchi, M. Baruscotti, D. DiFrancesco (2002)
Current-dependent Block of Rabbit Sino-Atrial Node If Channels by IvabradineThe Journal of General Physiology, 120
Ritesh Gupta, W.H. Tang, James Young (2004)
Patterns of β-blocker utilization in patients with chronic heart failure: Experience from a specialized outpatient heart failure clinicAmerican Heart Journal, 147
G. Lanza, K. Fox, F. Crea (2006)
Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing.Advances in cardiology, 43
A. Maggioni, U. Dahlström, G. Filippatos, O. Chioncel, M. Leiro, J. Drożdż, F. Fruhwald, L. Gullestad, D. Logeart, M. Metra, J. Parissis, H. Persson, P. Ponikowski, M. Rauchhaus, A. Voors, O. Nielsen, F. Zannad, L. Tavazzi (2010)
EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot)European Journal of Heart Failure, 12
Anders Bergström, B. Andersson, M. Edner, E. Nylander, H. Persson, U. Dahlström (2004)
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC)European Journal of Heart Failure, 6
O. Almgren, J. Engel, J. Jonason (1979)
CENTRAL EFFECTS OF BETA-ADRENOCEPTOR ANTAGONISTS
A. Maggioni, G. Sinagra, C. Opasich, E. Geraci, M. Gorini, E. Gronda, D. Lucci, G. Tognoni, E. Balli, L. Tavazzi (2003)
Treatment of chronic heart failure with β adrenergic blockade beyond controlled clinical trials: the BRING-UP experienceHeart, 89
M. Packer, M. Fowler, E. Roecker, A. Coats, H. Katus, H. Krum, P. Mohacsi, J. Rouleau, M. Tendera, C. Staiger, T. Holcslaw, I. Amann-Zalán, D. DeMets (2002)
Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) StudyCirculation: Journal of the American Heart Association, 106
M. Guglin (2013)
Heart rate reduction in heart failure: ivabradine or beta blockers?Heart Failure Reviews, 18
P. Colin, B. Ghaleh, L. Hittinger, X. Monnet, M. Slama, J. Giudicelli, A. Berdeaux (2002)
Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise.American journal of physiology. Heart and circulatory physiology, 282 2
I. Ekman, O. Chassany, M. Komajda, M. Böhm, J. Borer, I. Ford, L. Tavazzi, K. Swedberg (2011)
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.European heart journal, 32 19
(2002)
Few CHF patients achieve target dosages of beta blockers, risking hospitalizations and death
I. Oudejans, A. Mosterd, J. Bloemen, M. Valk, E. Velzen, J. Wielders, N. Zuithoff, F. Rutten, A. Hoes (2011)
Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional testsEuropean Journal of Heart Failure, 13
M. Bristow, E. Gilbert, W. Abraham, K. Adams, M. Fowler, R. Hershberger, S. Kubo, K. Narahara, H. Ingersoll, S. Krueger, S. Young, N. Shusterman (1996)
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.Circulation, 94 11
G. Sambuceti, M. Marzilli, P. Marraccini, J. Schneider-Eicke, E. Gliozheni, O. Parodi, A. L'Abbate (1997)
Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease.Circulation, 95 12
K Fox, I Ford, PG Steg, M Tendera, M Robertson (2008)
Ferrari R; BEAUTIFUL investigators; Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialLancet, 372
S. Stewart, A. Jenkins, S. Buchan, A. Mcguire, S. Capewell, J. McMurray (2002)
The current cost of heart failure to the National Health Service in the UKEuropean Journal of Heart Failure, 4
M. Fiuzat, D. Wojdyla, D. Kitzman, J. Fleg, S. Keteyian, W. Kraus, I. Piña, D. Whellan, C. O'connor (2012)
Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.Journal of the American College of Cardiology, 60 3
O. Traub, B. Berk (1998)
Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force.Arteriosclerosis, thrombosis, and vascular biology, 18 5
D. Veldhuisen, A. Cohen-Solal, M. Böhm, S. Anker, D. Babalis, M. Roughton, A. Coats, P. Poole‐Wilson, M. Flather (2009)
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).Journal of the American College of Cardiology, 53 23
A. Diaz, M. Bourassa, M. Guertin, J. Tardif (2005)
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.European heart journal, 26 10
A. Davie, C. Francis, L. Caruana, G. Sutherland, J. McMurray (1997)
Assessing diagnosis in heart failure: which features are any use?QJM : monthly journal of the Association of Physicians, 90 5
K. Swedberg, M. Komajda, M. Böhm, J. Borer, M. Robertson, L. Tavazzi, I. Ford (2012)
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.Journal of the American College of Cardiology, 59 22
J. Cohn, T. Levine, M. Olivari, Victoria Garberg, Dennis Lura, G. Francis, Ada Simon, T. Rector (1984)
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.The New England journal of medicine, 311 13
M. Gold (2011)
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialYearbook of Medicine, 2011
W. Kannel, C. Kannel, R. Paffenbarger, L. Cupples (1987)
Heart rate and cardiovascular mortality: the Framingham Study.American heart journal, 113 6
MJ Ackerman, SG Priori, S Willems, C Berul, R Brugada, H Calkins, AJ Camm, PT Ellinor, M Gollob, R Hamilton, RE Hershberger, DP Judge, H Marec, WJ McKenna, E Schulze-Bahr, C Semsarian, JA Towbin, H Watkins, A Wilde, C Wolpert, DP Zipes (2011)
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)Heart Rhythm, 8
A. Mosterd, A. Hoes (2007)
Clinical epidemiology of heart failureHeart, 93
K. Fox, I. Ford, G. Steg, M. Tendera, R. Ferrari (2008)
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialThe Lancet, 372
K. Swedberg, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. Smiseth, A. Gavazzi, A. Haverich, A. Hoes, T. Jaarsma, J. Korewicki, Samuel Lévy, C. Linde, J. López-Sendón, M. Nieminen, L. Pierard, W. Remme (2005)
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.European heart journal, 26 11
P. Mehta, S. Mcdonagh, P. Poole‐Wilson, Richard Grocott-Mason, S. Dubrey (2004)
Heart failure in a district general hospital: are target doses of beta-blockers realistic?QJM : monthly journal of the Association of Physicians, 97 3
L. Tavazzi (2003)
Heart rate as a therapeutic target in heart failureEuropean Heart Journal Supplements, 5
J. Kelder, M. Cramer, J. Wijngaarden, R. Tooren, A. Mosterd, K. Moons, J. Lammers, M. Cowie, D. Grobbee, A. Hoes (2011)
The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart FailureCirculation, 124
L. Gorkin, Nancy Norvell, Raymond Rosen, Ed Charles, Sally Shumaker, Kevin McIntyre, Robert Capone, J. Kostis, Raymond Niaura, Patricia Woods, James Hosking, Carlos Garces, Eileen Handberg, David Ahern, M. Follick (1993)
Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy.The American journal of cardiology, 71 12
M. Packer, A. Coats, M. Fowler, H. Katus, H. Krum, P. Mohacsi, J. Rouleau, M. Tendera, A. Castaigne, E. Roecker, M. Schultz, D. DeMets (2001)
Effect of carvedilol on survival in severe chronic heart failure.The New England journal of medicine, 344 22
W. Kosmala, D. Holland, A. Rojek, L. Wright, M. Przewłocka-Kosmala, T. Marwick (2013)
Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.Journal of the American College of Cardiology, 62 15
A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, D. Allaf, J. Vítovec, J. Aldershvile, M. Halinen, R. Dietz, K. Neuhaus, A. Jánosi, G. Thorgeirsson, P. Dunselman, L. Gullestad, J. Kuch, J. Herlitz, P. Rickenbacher, S. Ball, S. Gottlieb, P. Deedwania (2000)
Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)Survey of Anesthesiology, 44
G. Ferrari, A. Mazzuero, Laura Agnesina, A. Bertoletti, M. Lettino, C. Campana, P. Schwartz, L. Tavazzi (2008)
Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure ☆European Journal of Heart Failure, 10
J. Franciosa (2004)
The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example.The American journal of managed care, 10 7 Pt 2
M. Cheitlin (2008)
Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The Reversal of Ventricular Remodeling with Toprol-Xl (Revert) TrialYearbook of Cardiology, 2008
Ritesh Gupta, W. Tang, James Young (2004)
Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic.American heart journal, 147 1
M. Cheitlin (2011)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyYearbook of Medicine, 2011
J. Mant, J. Doust, A. Roalfe, P. Barton, M. Cowie, P. Glasziou, D. Mant, R. McManus, R. Holder, J. Deeks, K. Fletcher, M. Qume, S. Sohanpal, S. Sanders, F. Hobbs (2009)
Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care.Health technology assessment, 13 32
I. Moreno, Carlos Carlo, A. Pereira-Barretto (2013)
Optimized Treatment and Heart Rate Reduction in Chronic Heart FailureArquivos Brasileiros de Cardiologia, 101
K. Fox, I. Ford, P. Steg, M. Tendera, M. Robertson, R. Ferrari (2008)
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialThe Lancet, 372
C. Fonseca (2006)
Diagnosis of heart failure in primary careHeart Failure Reviews, 11
G. Fonarow, C. Yancy, N. Albert, A. Curtis, W. Stough, M. Gheorghiade, J. Heywood, M. Mehra, C. O'connor, D. Reynolds, M. Walsh (2007)
Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry.American heart journal, 154 1
Beta-blockers have become one of the cornerstones of treatment of patients with heart failure (HF) and depressed left ventricular function, but in clinical practice only 30–35 % of patients achieve the therapeutic target dose as established in randomized clinical trials. Moreover, high resting heart rate (HR) has emerged as a simple but relevant risk factor for cardiovascular events, including coronary artery disease and HF; also, it was found to have an independent prognostic value in patients with HF. Evidence that HR could be considered a good parameter to evaluate the quality of treatment in patients with HF has been suggested; of note, many patients maintain a resting HR ≥70 beats per minute despite optimal beta-blocker therapy. In recent years, a new drug able to reduce HR, ivabradine, has been introduced in clinical practice, and its use in the clinical setting of HF patients has been recommended by current European Society of Cardiology (ESC) guidelines. Here we review the evidence of the prognostic role of HR in systolic HF and the potential relationship between HR lowering and the beneficial effects of beta-blockers; we will also analyze the reasons why an appropriate use of these drugs is seldom achieved in clinical practice, and review the evidence for the use of ivabradine in systolic HF in the clinical setting.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Dec 11, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.